{Reference Type}: Journal Article
{Title}: Future of Time-in-Range Goals in the Era of Advanced Hybrid Closed-Loop Automated Insulin Delivery Systems.
{Author}: Akturk HK;Battelino T;Castañeda J;Arrieta A;van den Heuvel T;Cohen O;
{Journal}: Diabetes Technol Ther
{Volume}: 26
{Issue}: 0
{Year}: 2024 Mar
{Factor}: 7.337
{DOI}: 10.1089/dia.2023.0432
{Abstract}: The concept of maintaining blood glucose levels within the 70-180 mg/dL range, known as time-in-range, has raised questions regarding its representation of true physiological euglycemia. Some have speculated that focusing on the time spent within the 70-140 mg/dL range, introduced as time in tight range (TITR) through the International Consensus statement, could serve as a more precise metric for assessing normoglycemia in individuals with type 1 diabetes. This article delves into the current status of TITR as an emerging marker and explores how advanced hybrid closed-loop systems may offer a promising avenue for achieving this higher level of glycemic control.